Outlook Therapeutics (NASDAQ:OTLK) Earns Buy Rating from Chardan Capital

Chardan Capital reissued their buy rating on the stock Outlook Therapeutics (NASDAQ:OTLK – Free Report) in a research note issued to investors on Friday morning, Benzinga reports. Chardan Capital currently has a $53.00 price objective on the stock.

Separately, HC Wainwright reissued a buy rating and issued a $30.00 target price on shares of Outlook Therapeutics in a research note on Thursday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus price target of $45.55.

Check out our latest report on Outlook Therapeutics

Outlook Therapeutics Stock Performance

NASDAQ OTLK opened at $7.71 on Friday. The company has a fifty day moving average price of $7.68 and a 200 day moving average price of $8.05. The company has a market cap of $180.49 million, a P/E ratio of -0.68 and a beta of 0.71. Outlook Therapeutics has a one year low of $4.00 and a one year high of $29.20.

Institutional Trading by Outlook Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC purchased a new position in Outlook Therapeutics in the second quarter valued at approximately $75,000. Squarepoint Ops LLC purchased a new position in shares of Outlook Therapeutics in the second quarter valued at $232,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Outlook Therapeutics in the 2nd quarter worth $303,000. Great Point Partners LLC raised its position in shares of Outlook Therapeutics by 15.0% in the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after buying an additional 221,510 shares in the last quarter. Finally, LVW Advisors LLC purchased a new stake in Outlook Therapeutics in the second quarter valued at approximately $352,000. Institutional investors and hedge funds own 11.20% of the company’s shares.

About Outlook Therapeutics

(Get a free report)

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company focused on the development and commercialization of monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of its product candidate bevacizumab that is in Phase III clinical trial for the treatment of wet age-related macular degeneration and other retinal diseases.

Recommended articles

Get daily news and reviews for Outlook Therapeutics – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Outlook Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.